These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

869 related articles for article (PubMed ID: 28805820)

  • 1. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
    Dai X; Gan W; Li X; Wang S; Zhang W; Huang L; Liu S; Zhong Q; Guo J; Zhang J; Chen T; Shimizu K; Beca F; Blattner M; Vasudevan D; Buckley DL; Qi J; Buser L; Liu P; Inuzuka H; Beck AH; Wang L; Wild PJ; Garraway LA; Rubin MA; Barbieri CE; Wong KK; Muthuswamy SK; Huang J; Chen Y; Bradner JE; Wei W
    Nat Med; 2017 Sep; 23(9):1063-1071. PubMed ID: 28805820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
    Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
    Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
    Janouskova H; El Tekle G; Bellini E; Udeshi ND; Rinaldi A; Ulbricht A; Bernasocchi T; Civenni G; Losa M; Svinkina T; Bielski CM; Kryukov GV; Cascione L; Napoli S; Enchev RI; Mutch DG; Carney ME; Berchuck A; Winterhoff BJN; Broaddus RR; Schraml P; Moch H; Bertoni F; Catapano CV; Peter M; Carr SA; Garraway LA; Wild PJ; Theurillat JP
    Nat Med; 2017 Sep; 23(9):1046-1054. PubMed ID: 28805821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPOP-mediated degradation of BRD4 dictates cellular sensitivity to BET inhibitors.
    Dai X; Wang Z; Wei W
    Cell Cycle; 2017; 16(24):2326-2329. PubMed ID: 29108467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Insights into BET Client Recognition of Endometrial and Prostate Cancer-Associated SPOP Mutants.
    Ostertag MS; Hutwelker W; Plettenburg O; Sattler M; Popowicz GM
    J Mol Biol; 2019 May; 431(11):2213-2221. PubMed ID: 31026449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.
    Blee AM; Liu S; Wang L; Huang H
    Oncotarget; 2016 Jun; 7(25):38319-38332. PubMed ID: 27223260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.
    Wu F; Dai X; Gan W; Wan L; Li M; Mitsiades N; Wei W; Ding Q; Zhang J
    Cancer Lett; 2017 Jan; 385():207-214. PubMed ID: 27780719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis.
    Zhang Y; Fong KW; Mao F; Wang R; Allison DB; Napier D; He D; Liu J; Zhang Y; Chen J; Kong Y; Li C; Li G; Liu J; Li Z; Zhu H; Wang C; Liu X
    Cell Rep; 2024 Jul; 43(7):114431. PubMed ID: 38968071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
    Yan Y; Ma J; Wang D; Lin D; Pang X; Wang S; Zhao Y; Shi L; Xue H; Pan Y; Zhang J; Wahlestedt C; Giles FJ; Chen Y; Gleave ME; Collins CC; Ye D; Wang Y; Huang H
    EMBO Mol Med; 2019 Nov; 11(11):e10659. PubMed ID: 31559706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
    Geng C; He B; Xu L; Barbieri CE; Eedunuri VK; Chew SA; Zimmermann M; Bond R; Shou J; Li C; Blattner M; Lonard DM; Demichelis F; Coarfa C; Rubin MA; Zhou P; O'Malley BW; Mitsiades N
    Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6997-7002. PubMed ID: 23559371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.
    Jin X; Yan Y; Wang D; Ding D; Ma T; Ye Z; Jimenez R; Wang L; Wu H; Huang H
    Mol Cell; 2018 Aug; 71(4):592-605.e4. PubMed ID: 30057199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
    Shi Q; Zhu Y; Ma J; Chang K; Ding D; Bai Y; Gao K; Zhang P; Mo R; Feng K; Zhao X; Zhang L; Sun H; Jiao D; Chen Y; Sun Y; Zhao SM; Huang H; Li Y; Ren S; Wang C
    Mol Cancer; 2019 Nov; 18(1):170. PubMed ID: 31771591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BET Inhibitors Potentiate Chemotherapy and Killing of
    Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L
    Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPOP promotes ubiquitination and degradation of LATS1 to enhance kidney cancer progression.
    Wang L; Lin M; Chu M; Liu Y; Ma J; He Y; Wang ZW
    EBioMedicine; 2020 Jun; 56():102795. PubMed ID: 32460168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1.
    Zong D; Gu J; Cavalcante GC; Yao W; Zhang G; Wang S; Owonikoko TK; He X; Sun SY
    Cancer Res; 2020 Jun; 80(11):2380-2393. PubMed ID: 32156781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression.
    Zhang J; Chen M; Zhu Y; Dai X; Dang F; Ren J; Ren S; Shulga YV; Beca F; Gan W; Wu F; Lin YM; Zhou X; DeCaprio JA; Beck AH; Lu KP; Huang J; Zhao C; Sun Y; Gao X; Pandolfi PP; Wei W
    Dev Cell; 2019 Feb; 48(3):329-344.e5. PubMed ID: 30595538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
    Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N
    Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
    Tan Y; Ci Y; Dai X; Wu F; Guo J; Liu D; North BJ; Huo J; Zhang J
    Oncotarget; 2017 Jul; 8(29):47890-47901. PubMed ID: 28599312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
    Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
    Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
    Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.